Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

Alzheimer's disease (AD) is caused by synaptic and neuronal loss in the brain. One of the
characteristic hallmarks of AD is senile plaques containing amyloid β-peptide (Aβ). Aβ is …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Abstract Purpose of Review Early-onset Alzheimer's disease (EOAD), defined as
Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the …

Amyloid-β (Aβ) is present in humans as a 39-to 42-amino acid residue metabolic product of
the amyloid precursor protein. Although the two predominant forms, Aβ (1–40) and Aβ (1 …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

Filament assembly of amyloid-β peptides ending at residue 42 (Aβ42) is a central event in
Alzheimer's disease. Here, we report the cryo–electron microscopy (cryo-EM) structures of …

Increasing evidence has suggested that formation and propagation of misfolded aggregates
of 42-residue human amyloid β (Aβ (1–42)), rather than of the more abundant Aβ (1–40) …